- Home
- XP vs HALO Comparison
XP vs HALO Comparison
Compare XP & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XP | HALO |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.4B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | XP | HALO |
|---|---|---|
| Price | $16.46 | $68.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $22.80 | ★ $73.33 |
| AVG Volume (30 Days) | ★ 7.0M | 2.3M |
| Earning Date | 11-17-2025 | 11-03-2025 |
| Dividend Yield | ★ 1.09% | N/A |
| EPS Growth | 18.53 | ★ 56.68 |
| EPS | 1.76 | ★ 4.74 |
| Revenue | ★ $3,229,174,949.00 | $1,242,852,000.00 |
| Revenue This Year | $17.10 | $34.83 |
| Revenue Next Year | $12.69 | $24.84 |
| P/E Ratio | ★ $9.32 | $14.54 |
| Revenue Growth | 8.33 | ★ 31.19 |
| 52 Week Low | $10.82 | $47.00 |
| 52 Week High | $20.64 | $79.50 |
Technical Indicators
Market Signals| Indicator | XP | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 58.75 |
| Support Level | $15.85 | $61.23 |
| Resistance Level | $16.53 | $69.28 |
| Average True Range (ATR) | 0.48 | 1.69 |
| MACD | -0.14 | 0.69 |
| Stochastic Oscillator | 27.76 | 93.54 |
Price Performance
Historical ComparisonAbout XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.